AgomAb Therapeutics NV American Depositary Shares (NASDAQ:AGMB) — Stock Price
AgomAb Therapeutics NV American Depositary Shares (NASDAQ:AGMB) is currently trading at $10.53 USD, up 3.13% today. Over the past 52 weeks, shares have ranged between $9.61 and $17.82. This page tracks AgomAb Therapeutics NV American Depositary Shares's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see AgomAb Therapeutics NV American Deposita (AGMB) total market value.
AgomAb Therapeutics NV American Depositary Shares (AGMB) Stock Price Chart — Daily History & Trading Volume
The chart below tracks AgomAb Therapeutics NV American Depositary Shares's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
AgomAb Therapeutics NV American Depositary Shares Income Statement — Revenue, Profit & Earnings by Year
AgomAb Therapeutics NV American Depositary Shares's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Research & Development | $39.31 Million | $39.31 Million | $26.31 Million | $19.42 Million |
| SG&A | $9.82 Million | $9.82 Million | $6.00 Million | $4.49 Million |
| Total Operating Expenses | $48.02 Million | $48.02 Million | $31.19 Million | $22.63 Million |
| Operating Income | $-48.02 Million | $-48.02 Million | $-31.19 Million | $-22.63 Million |
| EBITDA | $-45.88 Million | $-45.88 Million | $-11.88 Million | $-10.74 Million |
| EBIT | $-46.20 Million | $-46.20 Million | $-11.98 Million | $-10.76 Million |
| Interest Expense | $67.00K | $67.00K | $31.00K | $45.00K |
| Income Before Tax | $-46.26 Million | $-46.26 Million | $-12.01 Million | $-10.81 Million |
| Income Tax Expense | $4.00K | $4.00K | $-619.00K | $-2.66 Million |
| Net Income | $-46.27 Million | $-46.27 Million | $-11.39 Million | $-8.14 Million |
AgomAb Therapeutics NV American Depositary Shares Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes AgomAb Therapeutics NV American Depositary Shares's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $153.71 Million | $206.36 Million | $171.26 Million | $101.00 Million | $84.00 Million |
| Total Current Assets | $121.24 Million | $173.84 Million | $139.47 Million | $71.08 Million | $54.43 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $30.10 Million | $0.00 | $0.00 | $40.00 Million | $0.00 |
| Net Receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | $8.61 Million | $8.61 Million | $8.61 Million | $8.61 Million | $8.61 Million |
| Total Liabilities | $22.80 Million | $18.28 Million | $19.82 Million | $34.75 Million | $41.63 Million |
| Total Current Liabilities | $18.59 Million | $9.13 Million | $10.88 Million | $29.72 Million | $33.71 Million |
| Long-term Debt | — | — | — | — | $690.00K |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | $130.90 Million | $188.08 Million | $151.44 Million | $66.25 Million | $42.36 Million |
| Retained Earnings | $-181.71 Million | $-119.18 Million | $-72.83 Million | $-61.44 Million | $-44.82 Million |
AgomAb Therapeutics NV American Depositary Shares Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how AgomAb Therapeutics NV American Depositary Shares generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | $-51.74 Million | $-46.83 Million | $-24.59 Million | $-18.97 Million |
| Capital Expenditures | $4.00K | $675.00K | $0.00 | $0.00 |
| Free Cash Flow | $-51.74 Million | $-47.50 Million | $-24.59 Million | $-18.97 Million |
| Investing Cash Flow | — | — | — | — |
| Financing Cash Flow | $-338.00K | $96.76 Million | $79.32 Million | $37.63 Million |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | $5.36 Million | $1.07 Million | $2.16 Million | $2.21 Million |
| Depreciation | $219.00K | $311.00K | $99.00K | $23.00K |
| Change in Cash | $-85.08 Million | $49.26 Million | $94.73 Million | $-25.92 Million |
AgomAb Therapeutics NV American Depositary Shares Earnings History — EPS Actual vs. Analyst Estimates
Track AgomAb Therapeutics NV American Depositary Shares's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 24, 2026 | -0.42 | — | — |
| Dec 31, 2025 | — | -41.04 | — |